Caplin Point Laboratories Ltdte (BSE: 524742) is a Chennai, Tamil Nadu-based company in the Pharmaceuticals industry. With a market capitalisation of ₹18,155 Cr, it ranks #388 by market cap among the 6,197 Indian listed companies on FinBizNet, and #6 of 63 in Pharmaceuticals. At ₹2,375.00 (as of 16 Nov 2026), the share price is 20.6% below its 52-week high of ₹2,990.00 and 58.3% above its 52-week low of ₹1,500.30. The share price is up 23.6% over one year and down 4.4% over three months.
| Current Price | ₹2,375.00 |
|---|---|
| Market Cap | ₹18,155 Cr |
| BSE Code | 524742 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Biotechnology and Life Sciences > Pharmaceuticals |
| P/E Ratio | 28.3 |
| Return on Equity | 19.94% |
| Return on Assets | 11.97% |
| 52-Week Range | ₹1,500.30 – ₹2,990.00 |
| 1-Year Price Change | +23.6% |
| 3-Month Price Change | -4.4% |
| Beta (1Y) | 0.4 |
| Dividend Yield | 0.34% |
| Headquarters | Chennai, Tamil Nadu |
| Website | www.caplinpoint.net |
| Revenue | ₹630 Cr |
|---|---|
| Net Profit | ₹182 Cr |
| Net Margin | 29.0% |
| EPS (Basic) | ₹23.44 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Caplin Point Laboratories Ltdte reported revenue of ₹630 Cr in Q2 FY27, up 17.9% from ₹534 Cr in Q2 FY26 and up 3.2% from ₹610 Cr in Q1 FY27. It posted a net profit of ₹182 Cr for the quarter, against a net profit of ₹160 Cr in Q2 FY26 (up 13.8%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹502 Cr (Q4 FY25) to ₹630 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹630 Cr | ₹182 Cr | 29.0% |
| Q1 FY27 | ₹610 Cr | ₹179 Cr | 29.3% |
| Q4 FY26 | ₹600 Cr | ₹173 Cr | 28.8% |
| Q3 FY26 | ₹543 Cr | ₹166 Cr | 30.6% |
| Q2 FY26 | ₹534 Cr | ₹160 Cr | 30.0% |
| Q1 FY26 | ₹510 Cr | ₹151 Cr | 29.5% |
| Q4 FY25 | ₹502 Cr | ₹145 Cr | 28.9% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 70.57% of Caplin Point Laboratories Ltdte's shares as of Sept 2026, unchanged from Sept 2025. Delivery averaged 46.0% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Caplin Point Laboratories Limited, together with its subsidiaries, engages in the development, production, marketing, and export of generic formulations and branded products in India. The company provides tablets, capsules, injections, ophthalmic, liquid orals, softgel capsules, ointments, creams and gels, powder for injections, suppositories, ovules, pre-mix bag formulations, inhalers, and sprays and IV infusion. It also provides dry and syrups, lyophilized vials, prefilled syringes, emulsion injection, sachets, liquid injectables, topicals, pre-filled syringes, and pre-mix bags. Caplin Point Laboratories Limited was incorporated in 1990 and is headquartered in Chennai, India.
1. Pharmaceutical Formulations-This segment produces, develops, markets, and exports generic formulations and branded products. It provides liquid injections, lyophilised injections, opthalmic products, liquid orals, capsules, tablets, softgel capsules, suppositories and ovules, dry syrups, topicals, inhalers, IV infusion products, dermo cosmetics, and other products, as well as powders for injection.
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Abbott India Ltd. | ₹56,531 Cr | 36.3 | 34.46% | ₹1,814 Cr | -8.1% |
| Emcure Pharmaceuticals Ltd | ₹42,344 Cr | 47.9 | 19.57% | ₹2,820 Cr | +73.3% |
| Ajanta Pharma Limited | ₹41,474 Cr | 39.4 | 25.39% | ₹1,794 Cr | +27.8% |
| Piramal Pharma Ltd | ₹32,600 Cr | n/m | -4.00% | ₹2,617 Cr | +22.8% |
| RUBICON RESEARCH LIMITED | ₹28,526 Cr | 112.3 | 19.14% | ₹576 Cr | +162.7% |
| Caplin Point Laboratories Ltdte | ₹18,155 Cr | 28.3 | 19.94% | ₹630 Cr | +23.6% |
| Pfizer Ltd. | ₹17,811 Cr | 24.5 | 17.16% | ₹727 Cr | -24.2% |
| Eris Lifesciences Ltd | ₹17,691 Cr | 28.3 | 18.07% | ₹892 Cr | -17.5% |
| Astrazeneca Pharma India Ltd. | ₹16,078 Cr | 85.9 | 22.82% | ₹729 Cr | -34.3% |
Listed by market capitalisation. Ratios are shown for context only.
Caplin Point Laboratories Ltdte is trading at ₹2,375.00, with a market capitalisation of ₹18,155 Cr.
Caplin Point Laboratories Ltdte operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Pharmaceuticals).
Caplin Point Laboratories Ltdte has a P/E of 28.3 and a return on equity of 19.94%.
Caplin Point Laboratories Ltdte is listed on the BSE under the scrip code 524742.
Caplin Point Laboratories Ltdte's share price is up 23.6% over one year and down 4.4% over three months. Its 52-week range is ₹1,500.30 to ₹2,990.00.
In Q2 FY27, Caplin Point Laboratories Ltdte reported revenue of ₹630 Cr and net profit of ₹182 Cr, with basic EPS of ₹23.44 (consolidated, parsed from the company's exchange filing).
Caplin Point Laboratories Ltdte reported revenue of ₹630 Cr in Q2 FY27, up 17.9% from ₹534 Cr in Q2 FY26 and up 3.2% from ₹610 Cr in Q1 FY27.
Promoters held 70.57% of Caplin Point Laboratories Ltdte's shares as of Sept 2026, unchanged from Sept 2025.
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.